CNS Pharmaceuticals Appoints Rami Levin as CEO to Advance Brain Cancer Pipeline

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) has announced a leadership transition with Rami Levin, MBA, appointed as president and chief executive officer, effective January 1, 2026. Levin succeeds John Climaco, who has stepped down from the CEO role. The biopharmaceutical company focuses on developing treatments for primary and metastatic cancers of the brain and central nervous system.

Levin brings nearly three decades of global leadership experience across oncology, neurology and rare diseases to CNS Pharmaceuticals. His background includes a track record of advancing late-stage clinical programs, scaling organizations and leading strategic turnarounds. This experience positions the company to advance its pipeline and enter its next phase of development as it works on treatments for some of the most challenging cancers affecting the brain and central nervous system.

The company's lead drug candidate, TPI 287, represents a significant area of focus. TPI 287 is an abeotaxane that stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. Initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat central nervous system tumors, which represents a critical advancement in neuro-oncology given the historical difficulty of delivering effective treatments past this protective barrier.

TPI 287 has been tested in over 350 patients in clinical trials as both a monotherapy and in combination with bevacizumab for various conditions. These include recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date, TPI 287 appears to have both an excellent safety profile and high tolerability among patients, which is particularly important for individuals already dealing with the debilitating effects of cancer and its treatments.

The leadership change comes at a pivotal time for CNS Pharmaceuticals as it continues developing its pipeline of anti-cancer drug candidates. The appointment of an executive with Levin's extensive experience in oncology and rare diseases signals the company's commitment to advancing its clinical programs through late-stage development and potential commercialization. For patients with brain and central nervous system cancers, who often face limited treatment options and poor prognoses, advancements in this field could represent meaningful progress toward more effective therapies.

The broader neuro-oncology industry may see increased attention and investment as companies like CNS Pharmaceuticals work to address the significant unmet medical need in treating brain cancers. The company's latest news and updates are available in its newsroom at https://ibn.fm/CNSP. The press release announcing the leadership transition was distributed through MissionIR, a specialized communications platform that assists investor relations firms with syndicated content to enhance company visibility within the investment community.